Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

144.07
+1.360.95%
Volume:245.68K
Turnover:35.33M
Market Cap:274.89B
PE:21.78
High:144.55
Open:143.00
Low:142.91
Close:142.71
52wk High:170.46
52wk Low:121.57
Shares:1.91B
Float Shares:1.85B
Volume Ratio:1.39
T/O Rate:0.01%
Dividend:4.67
Dividend Rate:3.24%
EPS(TTM):6.61
EPS(LYR):7.15
ROE:30.35%
ROA:10.25%
PB:6.62
PE(LYR):20.15

Loading ...

Novartis Poised for Sales Growth Acceleration

Dow Jones
·
11 mins ago

Novartis AG Rises Wednesday, Outperforms Market

Dow Jones
·
21 hours ago

European Pharma Leaders Push for National Reforms to Boost Investment

Dow Jones
·
Sep 22

Novartis AG Rises Monday, Underperforms Market

Dow Jones
·
Sep 22

Novartis AG Falls Friday, Outperforms Market

Dow Jones
·
Sep 19

Novartis announces positive CHMP opinion for Cosentyx

TIPRANKS
·
Sep 18

Novartis Halts ALS Drug Development After Phase 2 Trial Miss

MT Newswires Live
·
Sep 17

Novartis AG Rises Wednesday

Dow Jones
·
Sep 17

Novartis to End ALS Trial Amid String of Study Failures

Dow Jones
·
Sep 16

Legend Biotech Taps Novartis Veteran Zhang as CEO

Reuters
·
Sep 15

NYSE Order Imbalance 99880.0 Shares on Sell Side

THOMSON REUTERS
·
Sep 15

Novartis AG Rises Monday, Outperforms Market

Dow Jones
·
Sep 15

Movement Alert|Novartis AG Rises 3.19% in Regular Trading, Major Shareholder Pushes for Board Overhaul as Analysts Upgrade Rating

Market Focus
·
Sep 14

Movement Alert|Novartis AG Rises 3.04% in Pre-Market Trading, Major Shareholder Pushes for Board Overhaul as Brokerages Upgrade Ratings

Market Focus
·
Sep 14

Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness - Heard on the Street

Dow Jones
·
Sep 12

Novartis: More Pain on the Way?

Dow Jones
·
Sep 12

Novartis AG Falls Friday, Underperforms Market

Dow Jones
·
Sep 12

Novartis Needs to Make Progress on Pipeline to Justify Valuation

Dow Jones
·
Sep 11

Novartis shareholder calls for board changes, Reuters reports

TIPRANKS
·
Sep 10

Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures

MT Newswires Live
·
Sep 10